Harnessing the AUTOTAC Platform for Development of a First-In-Class Tau Aggregate Degrader: Bridging the Gap Between Discovery, Preclinical Candidacy & Clinical Trials
Time: 9:00 am
day: Conference Day One
Details:
- Development of a novel targeted protein degradation platform (AUTOTAC) via p62-dependent selective macro-autophagy
- Application of the AUTOTAC platform to develop a first-in-class tau aggregate degrader ready for clinical trials
- Translation of academic discovery into industry-level drug development
